Floatz logo

Romidepsin

Neutropenia

Fairview University Medical CenterSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Neutropenia cohort.

Asset / SponsorPhaseRating
f-627
EVIVE Biotechnology
Phase 3BBB
FILGRASTIM
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 4BBB
PEGFILGRASTIM
Affiliated Hospital of North Sichuan Medical College
Phase 4BBB
Cefepime
Hospital Universitari Vall d'Hebron Research Institute
Phase 4BB
Docetaxel
Spectrum Pharmaceuticals, Inc
Phase 3BB

View all 50 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →